Healthcare Industry News: Dade Behring
News Release - April 16, 2007
Dr. Paul A. Foster Joins Reata as Chief Medical OfficerReata Relocates to Accommodate Growing Organization
IRVING, Texas--(HSMN NewsFeed)--Reata Pharmaceuticals, Inc. today announced that Paul A. Foster, M.D. has recently joined Reata as the Chief Medical Officer and Vice President of Clinical and Regulatory Affairs. Dr. Foster joins Reata's newly opened offices in Irving, Texas.
"We are delighted to add Dr. Paul Foster to the Reata management team at this important time in Reata's development," commented Warren Huff, Reata's CEO. "As Reata prepares to launch advanced clinical trials of two important new cancer therapies, we felt it was critical to add a seasoned medical executive like Dr. Foster to the team."
Reata's growth has been driven by success with the company's two lead clinical programs, RTA 744 and RTA 402, and its discovery platform. The company has added significant personnel to its clinical organization to support the initiation of six Phase 2 clinical trials during 2007. Additionally, Reata has achieved Proof of Concept for its innovative discovery platform based on protein misfolding and is expanding the capabilities of its drug discovery operations in this area.
Dr. Foster has held leadership positions at IDEC Pharmaceuticals Corporation, Biogen Idec and Alpha Therapeutic Corporation and has many years of experience in clinical development for growing biotech companies. He also has experience in the medical device arena, previously holding director positions at Abbot Laboratories and Dade Behring. He is Board Certified in Internal Medicine and Hematology. He received his medical training at Duke University and his undergraduate degree in Chemistry from the University of Michigan.
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com
Source: Reata Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.